Fiskus Warren W

Show results for

Transcriptomics (2)
Proteomics (2)

Organisms

Homo sapiens (2)
seawater metagenome (2)
Thermus thermophilus HB27 (2)
Blastocrithidia nonstop (2)
Vespa crabro (2)
Campylobacter jejuni subsp. jejuni NCTC 11168-PO (2)
Braarudosphaera bigelowii (2)
Phlebiopsis gigantea 11061_1 CR5-6 (2)
Dermatophagoides (2)
Blomia tropicalis (2)
Saccharum hybrid cultivar BO91 (2)
Saccharum hybrid cultivar CoJ64 (2)
Trioza sp. 8 NS74B (2)
synthetic RNA (2)
Candidatus Thiosymbion (2)
Colletotrichum falcatum (2)
Klebsiella pneumoniae IS43 (2)
Escherichia coli O11 (2)
Gammaproteobacteria (2)
Camelus dromedarius papillomavirus 3 (2)
Epinephelus lanceolatus (2)
Oleispira antarctica (2)
Actinidia deliciosa (2)
Rosa hybrid cultivar (2)
Geobacillus sp. E263 (2)
Norwalk virus (2)
Doryteuthis pealeii (2)
Nezara viridula (2)
Methylophaga thiooxydans DMS010 (2)
Salvelinus namaycush (2)

Repository

biostudies-arrayexpress (2)
pride (2)

Disease

Acute leukemia (2)

Technology Type

Mass Spectrometry (2)
Shotgun proteomics (2)

Publication Date

2025 (2)
2015 (1)
2014 (1)

Study type

Transcription profiling by array (2)

Release Date

2015 (1)
2014 (1)

Lab affiliation

Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030 (2)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells

We treated patient-derived mutant NPM1-and FLT3-ITD expressing AML cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for 48 hours to determine FHD-286-mediated changes to the AML proteome.

ORGANISM(S): Homo sapiens (Human)

2025-05-06 | PXD047967 | Pride

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells

We treated MLL1-rearranged AML MOLM13 cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for different time intervals (up to 48 hours) to measure the time-dependent changes to the AML proteome

ORGANISM(S): Homo sapiens (Human)

2025-05-26 | PXD047965 | Pride

Mll1-rearranged aml Chromatin remodelers Fhd-286

Synergistic activity of BET protein antagonist-based combinations in Mantle Cell Lymphoma cells sensitive or resistant to ibrutinib

To determine the global transcriptome changes in mantle cell lymphoma cells following treatment with the BET bromodomain antagonist, JQ1 Mantle Cell Lymphoma (MCL) cells exhibit increased B cell receptor and NFkB activities. The BET protein BRD4 is essential for the transcriptional activity of NFkB....

ORGANISM(S): Homo sapiens

2015-12-31 | E-GEOD-70651 | biostudies-arrayexpress

Effects of SPOP on gene expression in prostate cancer

SPOP is a ubiquitin ligase adaptor frequently mutated in prostate cancer. It is involved in ubiquitination and degradation of substrate proteins. We examined the impact of wild-type and mutant SPOP on the transcriptional profile of prostate cancer cells. We cloned several naturally occurring (in hum...